- Home
- MNTK vs MLYS Comparison
MNTK vs MLYS Comparison
Compare MNTK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- MLYS
- Stock Information
- Founded
- MNTK 1980
- MLYS 2019
- Country
- MNTK United States
- MLYS United States
- Employees
- MNTK N/A
- MLYS N/A
- Industry
- MNTK Natural Gas Distribution
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- MNTK Utilities
- MLYS Health Care
- Exchange
- MNTK Nasdaq
- MLYS Nasdaq
- Market Cap
- MNTK 586.4M
- MLYS 609.7M
- IPO Year
- MNTK 2021
- MLYS 2023
- Fundamental
- Price
- MNTK $3.95
- MLYS $12.35
- Analyst Decision
- MNTK Hold
- MLYS Strong Buy
- Analyst Count
- MNTK 2
- MLYS 2
- Target Price
- MNTK $6.00
- MLYS $30.00
- AVG Volume (30 Days)
- MNTK 170.7K
- MLYS 154.4K
- Earning Date
- MNTK 11-12-2024
- MLYS 11-11-2024
- Dividend Yield
- MNTK N/A
- MLYS N/A
- EPS Growth
- MNTK 42.11
- MLYS N/A
- EPS
- MNTK 0.16
- MLYS N/A
- Revenue
- MNTK $194,849,000.00
- MLYS N/A
- Revenue This Year
- MNTK $21.28
- MLYS N/A
- Revenue Next Year
- MNTK $31.59
- MLYS N/A
- P/E Ratio
- MNTK $24.39
- MLYS N/A
- Revenue Growth
- MNTK 9.63
- MLYS N/A
- 52 Week Low
- MNTK $3.38
- MLYS $7.29
- 52 Week High
- MNTK $9.38
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- MNTK 37.86
- MLYS 46.36
- Support Level
- MNTK $3.80
- MLYS $11.61
- Resistance Level
- MNTK $4.35
- MLYS $13.38
- Average True Range (ATR)
- MNTK 0.20
- MLYS 0.78
- MACD
- MNTK 0.02
- MLYS -0.05
- Stochastic Oscillator
- MNTK 22.86
- MLYS 28.68
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a United States-based renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments: Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.